Profile data is unavailable for this security.
About the company
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. It is developing Uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is a drug candidate that simultaneously targets both E-selectin and a chemokine receptor (CXCR4).
- Revenue in USD (TTM)10.00k
- Net income in USD-37.28m
- Incorporated2003
- Employees35.00
- LocationGlycoMimetics Inc9708 Medical Center DriveROCKVILLE 20850United StatesUSA
- Phone+1 (240) 243-1201
- Fax+1 (240) 243-1018
- Websitehttps://glycomimetics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Unicycive Therapeutics Inc | 0.00 | -37.82m | 18.77m | 14.00 | -- | -- | -- | -- | -1.26 | -1.26 | 0.00 | 0.5779 | 0.00 | -- | -- | 0.00 | -92.81 | -218.20 | -221.58 | -609.54 | -- | -- | -- | -3,877.49 | -- | -- | 0.00 | -- | -29.02 | -- | -73.95 | -- | -- | -- |
Indaptus Therapeutics Inc | 0.00 | -14.98m | 18.79m | 7.00 | -- | 2.01 | -- | -- | -1.78 | -1.78 | 0.00 | 1.10 | 0.00 | -- | -- | 0.00 | -87.86 | -66.55 | -97.46 | -81.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.68 | -- | -- | -- |
MEI Pharma Inc | 66.75m | 26.16m | 18.92m | 46.00 | 0.7235 | 0.3708 | 0.7138 | 0.2835 | 3.93 | 3.93 | 10.02 | 7.66 | 0.6498 | -- | 29.15 | 1,451,174.00 | 25.46 | -25.31 | 30.38 | -28.59 | -- | -- | 39.18 | -122.05 | -- | -- | 0.00 | -- | 19.95 | 97.56 | 41.53 | -- | -- | -- |
Eom Pharmaceutical Holdings Inc | 0.00 | -4.93m | 19.14m | 3.00 | -- | -- | -- | -- | -0.0435 | -0.0435 | 0.00 | -0.0212 | -- | -- | -- | 0.00 | -- | -126.34 | -- | -171.37 | -- | -- | -- | -- | -- | -- | 7.41 | -- | -- | -- | -254.37 | -- | -- | -- |
Ibio Inc | 50.00k | -17.13m | 19.66m | 26.00 | -- | 0.7811 | -- | 393.24 | -13.10 | -17.09 | 0.0262 | 2.92 | 0.0011 | -- | 0.0065 | 1,923.08 | -36.24 | -28.09 | -67.39 | -32.63 | -- | -- | -34,258.00 | -1,467.30 | -- | -- | 0.3666 | -- | -100.00 | -- | 0.9764 | -- | 42.90 | -- |
Goldenwell Biotech Inc | 1.08k | -114.27k | 19.80m | -- | -- | 368.37 | -- | 18,333.33 | -0.0012 | -0.0012 | 0.00001 | 0.0005 | 0.0052 | 0.0035 | -- | -- | -54.62 | -- | -54.97 | -- | 43.52 | -- | -10,580.56 | -- | 20.18 | -- | 0.00 | -- | -95.10 | -- | 88.13 | -- | -- | -- |
GlycoMimetics Inc | 10.00k | -37.28m | 19.98m | 35.00 | -- | 0.6911 | -- | 1,998.40 | -0.5791 | -0.5791 | 0.0002 | 0.4486 | 0.0002 | -- | 0.0581 | 285.71 | -72.29 | -43.60 | -81.84 | -47.82 | -- | -- | -372,767.40 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
Aspira Women's Health Inc | 8.99m | -14.74m | 20.17m | 64.00 | -- | -- | -- | 2.24 | -1.33 | -1.33 | 0.8698 | -0.1104 | 0.9637 | 13.76 | 5.83 | 140,484.40 | -158.00 | -110.58 | -395.41 | -151.88 | 58.84 | 45.23 | -163.95 | -334.08 | 1.11 | -- | 3.10 | -- | 11.85 | 24.56 | 44.15 | -- | -26.65 | -- |
Forte Biosciences Inc | 0.00 | -32.14m | 20.37m | 11.00 | -- | 0.7093 | -- | -- | -1.03 | -1.03 | 0.00 | 0.7882 | 0.00 | -- | -- | 0.00 | -93.54 | -72.06 | -104.30 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
Singular Genomics Systems Inc | 2.49m | -96.21m | 20.70m | 255.00 | -- | 0.132 | -- | 8.31 | -39.39 | -39.39 | 1.02 | 63.47 | 0.0091 | 0.233 | 32.98 | 9,764.71 | -35.33 | -- | -37.29 | -- | -41.49 | -- | -3,863.90 | -- | 9.54 | -- | 0.0614 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
Vincerx Pharma Inc | 0.00 | -38.25m | 20.72m | 42.00 | -- | -- | -- | -- | -1.79 | -1.79 | 0.00 | -0.029 | 0.00 | -- | -- | 0.00 | -130.68 | -- | -205.70 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 36.24 | -- | -- | -- |
Viracta Therapeutics Inc | 0.00 | -47.99m | 20.85m | 40.00 | -- | 3.71 | -- | -- | -1.24 | -1.24 | 0.00 | 0.2821 | 0.00 | -- | -- | 0.00 | -75.51 | -86.35 | -112.64 | -106.38 | -- | -- | -- | -11,853.94 | -- | -84.18 | 0.6277 | -- | -- | -- | -3.78 | -- | -- | -- |
NanoViricides Inc | 0.00 | -9.51m | 21.03m | 7.00 | -- | 1.97 | -- | -- | -0.8115 | -0.8115 | 0.00 | 0.9017 | 0.00 | -- | -- | 0.00 | -63.30 | -43.54 | -65.85 | -46.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.94 | -- | -8.90 | -- |
Bullfrog AI Holdings, Inc. | 65.00k | -5.95m | 21.20m | 4.00 | -- | 3.12 | -- | 326.10 | -0.8903 | -0.8903 | 0.0097 | 0.8667 | 0.0094 | -- | -- | 16,250.00 | -85.49 | -- | -103.85 | -- | 92.00 | -- | -9,129.42 | -- | -- | -278.20 | 0.0694 | -- | 550.00 | -- | -91.11 | -- | -- | -- |
Aprea Therapeutics Inc | 963.81k | -12.72m | 21.29m | 7.00 | -- | 0.736 | -- | 22.09 | -3.32 | -3.32 | 0.2503 | 5.57 | 0.0296 | -- | -- | 137,687.10 | -39.00 | -68.66 | -43.83 | -77.19 | -- | -- | -1,319.45 | -42,112.84 | -- | -- | 0.00 | -- | -- | -- | 87.32 | -- | 90.61 | -- |
Holder | Shares | % Held |
---|---|---|
BVF Partners LPas of 31 Mar 2024 | 9.54m | 14.81% |
Invus Public Equities Advisors LLCas of 31 Mar 2024 | 8.59m | 13.32% |
Octagon Capital Advisors LPas of 31 Mar 2024 | 3.00m | 4.65% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.75m | 4.26% |
AXA Investment Managers UK Ltd.as of 31 Mar 2024 | 1.59m | 2.46% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 1.11m | 1.73% |
Millennium Management LLCas of 31 Mar 2024 | 746.95k | 1.16% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 715.89k | 1.11% |
Susquehanna Financial Group LLLPas of 31 Mar 2024 | 510.91k | 0.79% |
Geode Capital Management LLCas of 31 Mar 2024 | 505.15k | 0.78% |